Abstract：Morin is a kind of natural pyran ring flavonoid from Moraceae plants. Mulberry branches, mulberry leaves, white mulberry root barks and other mulberry-derived herbs are traditional Chinese medicines, which often appear in the prescriptions for treatment of kidney injury-related diseases. Animal experiments and in vitro experiments have shown that morin has a wide range of pharmacological activities, such as antioxidant, anti-inflammatory, regulation of cell apoptosis and aberrant proliferation, and has great potential in alleviating diseases such as diabetes, gout, arthritis and hypertension. At the same time, a large number of studies have shown that morin can alleviate kidney injury diseases through a variety of mechanisms, which is worth further exploration. In this review, the mechanism of morin in alleviating kidney injury is expounded and analyzed to provide reference for related studies. Although the pharmacological activity of morin in alleviating kidney injury has been demonstrated in animals and in vitro experiments, there are still problems of low bioavailability,few clinical studies, and so on. More studies are needed in order to achieve the clinical application of morin.
李世杰, 杜宇凡, 万子彦, 王婉如, 张冬梅. 桑色素缓解肾脏损伤的药理学机制研究进展[J]. 中国药学杂志, 2023, 58(1): 18-25.
LI Shi-jie, DU Yu-fan, WAN Zi-yan, WANG Wan-ru, ZHANG Dong-mei. Progress in Research on Pharmacological Mechanism of Morin in Alleviating Renal Injury. Chinese Pharmaceutical Journal, 2023, 58(1): 18-25.
CHAN E W, LYE P Y,WONG S K. Phytochemistry, pharmacology, and clinical trials of Morus alba[J]. Chin J Nat Med(中国天然药物), 2016, 14(1):17-30.
[2]
CASELLI A, CIRRI P, SANTI A, et al. Morin:A promising natural drug[J]. Curr Med Chem, 2016, 23(8):774-791.
[3]
DU H, GAI Y, ZHANG T. Effect of Wusangyin on early diabetic nephropathy with spleen and kidney qi deficiency[J]. Shandong Med J(山东医药),2015,55(46):42-43.
[4]
AN Y J, Treating 76 cases of diabetic nephropathy with Shutangyushenyin[J]. Shaanxi J Tradit Chin Med(陕西中医), 2005, 26(4):307-308.
[5]
WANG C P, WANG X, ZHANG X, et al. Morin improves urate excretion and kidney function through regulation of renal organic ion transporters in hyperuricemic mice[J]. J Pharm Pharm Sci, 2010, 13(3):411-427.
[6]
PRAHALATHAN P, KUMAR S,RAJA B. Effect of morin, a flavonoid against DOCA-salt hypertensive rats:a dose dependent study[J]. Asian Pac J Trop Biomed, 2012, 2(6):443-448.
[7]
KUZU M, YıLDıRıM S, KANDEMIR F M, et al. Protective effect of morin on doxorubicin-induced hepatorenal toxicity in rats[J]. Chem Biol Interact, 2019, 308:89-100.
[8]
SINHA K, GHOSH J,SIL P C. Morin and its role in chronic diseases[J]. Adv Exp Med Biol, 2016, 928:453-471.
[9]
TAGUCHI N, YURIGUCHI M, ANDO T, et al. Flavonoids with two OH groups in the B-ring promote pigmented hair regeneration[J]. Biol Pharm Bull, 2019, 42(9):1446-1449.
[10]
HASSAN F U, ARSHAD M A, LI M, et al. Potential of mulberry leaf biomass and its flavonoids to improve production and health in ruminants:mechanistic insights and prospects[J]. Animals(Basel), 2020, 10(11):2076. Doi:10.3390/ani10112076.
[11]
KONGPICHITCHOKE T, HSU J L,HUANG T C. Number of hydroxyl groups on the B-ring of flavonoids affects their antioxidant activity and interaction with phorbol ester binding site of PKCδ C1B domain:In vitro and in silico studies[J]. J Agric Food Chem, 2015, 63(18):4580-4586.
[12]
WANG L, TU Y C, LIAN T W, et al. Distinctive antioxidant and antiinflammatory effects of flavonols[J]. J Agric Food Chem, 2006, 54(26):97989804.
[13]
PRADHAN A B, BHUIYA S, HAQUE L, et al. Role of hydroxyl groups in the B-ring of flavonoids in stabilization of the Hoogsteen paired third strand of Poly(U).Poly(A)*Poly(U) triplex[J]. Arch Biochem Biophys, 2018, 637:9-20.
[14]
NOOR H, CAO P, RALEIGH D P. Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers[J]. Protein Sci, 2012, 21(3):373-382.
[15]
XIE M X, LONG M, LIU Y, et al. Characterization of the interaction between human serum albumin and morin[J]. Biochim Biophys Acta, 2006, 1760(8):1184-1191.
[16]
JIANG N Z, BO M, WU Z P,et al. A review on the chemical constituents and pharmacological activity stuidies of Ramulus Mori[J]. Jiangsu Seric(江苏蚕业), 2006, 28(2):47-49.
[17]
LIU H Y. Treatment of 87 cases of diabetic peripheral neuritis with Erzhi decoction[J]. Chin J Clin Rehabil(中国临床康复), 2003, 7(9):1461.
[18]
JING W H, WU W J, YAN R, et al. Resear chprogressin chemical, pharmacological and pharmacokinetic studies of Mori Cortex, a Chinese medicinal herb belonging to Lung Meridian[J]. Chin Med(世界中医药), 2014, 9(1):109-112,116.
[19]
COSTA J P L, BRITO H O, GALVÃO-MOREIRA L V, et al. Randomized double-blind placebo-controlled trial of the effect of Morus nigra L.(black mulberry) leaf powder on symptoms and quality of life among climacteric women[J]. Int J Gynaecol Obstet, 2020, 148(2):243-252.
[20]
SHIWQ, MINYL, ZHANGYQ, et al. Effect of mulberry water decoction onxero phthalmia of menopau salfemales[J]. Chin J Gerontol(中国老年学杂志), 2019, 39(23):5733-5737.
[21]
LI Y C, XU S R. Clinical observation on treating dry eye with the Sangbaipi decoction[J]. Clin J Chin Med(中医临床研究), 2012, 4(20):107-108.
[22]
RICHE D M, RICHE K D, EAST H E, et al. Impact of mulberry leaf extract on type 2 diabetes(Mul-DM):A randomized, placebo-controlled pilot study[J]. Complement Ther Med, 2017, 32:105-108.
[23]
LOWN M, FULLER R, LIGHTOWLER H, et al. Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults:Results of a randomised double-blind placebo-controlled study[J]. PLoS One, 2017, 12(2):e0172239. Doi:10.1371/journal.pone.0172239.
[24]
ARAMWIT P, SUPASYNDH O, SIRITIENTHONG T, et al. Mulberry leaf reduces oxidation and c-reactive protein level in patients with mild dyslipidemia[J]. Biomed Res Int, 2013, 2013:787981.Doi:10.1155/2013/787981.
[25]
ARAMWIT P, PETCHARAT K,SUPASYNDH O. Efficacy of mulberry leaf tablets in patients with mild dyslipidemia[J]. Phytother Res, 2011, 25(3):365-369.
[26]
WANG H, GU C J, TONG X L. Mulberry leaves, mulberry branches and Cortex Mori in the treatment of diabetes——Three prescription by professor Tong Xiaolin[J]. Jilin J Chin Med(吉林中医药), 2019, 39(11):1463-1465.
[27]
WEI H, ZHU J J, LIU X Q, et al. Review of bioactive compounds from root barks of Morus plants(Sang-Bai-Pi) and their pharmacological effects[J]. Cogent Chem,2016, 2(1):212-320.
[28]
YUAN T, LIU Z Y, ZHANG P Q. Professor Zhang Peiqing's experience in treating proteinuria with self-made shenyan Xiaobai recipe[J]. Chin J Integr Tradit Western Nephrol(中国中西医结合肾病杂志), 2016, 17(11):950-951.
[29]
SONG F L. Clinical observation of mulberry branches granule combined with cyclophosphamide in treatment of hormone resistant nephrotic syndrome[J]. Chin Forei Med Res(中外医学研究), 2015, 13(20):38-39.
[30]
SHI Y W, WANG C P, WANG X, et al. Uricosuric and nephroprotective properties of Ramulus Mori ethanol extract in hyperuricemic mice[J]. J Ethnopharmacol, 2012, 143(3):896-904.
[31]
SATO V H, CHEWCHINDA S, PARICHATIKANOND W, et al. In vitro and in vivo evidence of hypouricemic and anti-inflammatory activities of Maclura cochinchinensis(Lour.) Corner heartwood extract[J]. J Tradit Complement Med, 2020, 10(1):85-94.
[32]
TIAN Y, CHEN K, XIE Z, et al. The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the dyslipidemia international study[J]. BMC Cardiovasc Disord, 2015, 15:66.Doi:10.1186/s12872-015-0059-4.
[33]
KUSHIYAMA A, TANAKA K, HARA S, et al. Linking uric acid metabolism to diabetic complications[J]. World J Diabetes, 2014, 5(6):787-795.
[34]
WEI C Y, SUN C C, WEI J C, et al. Association between hyperuricemia and metabolic syndrome: an epidemiological study of a labor force population in Taiwan[J]. Biomed Res Int, 2015, 2015:369179. Doi:10.1155/2015/369179.
[35]
ROUGHLEY M J, BELCHER J, MALLEN C D, et al. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies[J]. Arthritis Res Ther, 2015, 17(1):90. Doi:10.1186/s13075-015-0610-9.
[36]
STAMP L K, DAY R O,YUN J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk[J]. Nat Rev Rheumatol, 2016, 12(4):235-242.
[37]
ROBBINS N, KOCH S E, TRANTER M, et al. The history and future of probenecid[J]. Cardiovasc Toxicol, 2012, 12(1):1-9.
[38]
SCHLESINGER N. Management of acute and chronic gouty arthritis:present state-of-the-art[J]. Drugs, 2004, 64(21):2399-2416.
[39]
YU Z, FONG W P,CHENG C H. The dual actions of morin(3,5,7,2′,4′-pentahydroxyflavone) as a hypouricemic agent:Uricosuric effect and xanthine oxidase inhibitory activity[J]. J Pharmacol Exp Ther, 2006, 316(1):169-175.
[40]
YU Z, FONG W P,CHENG C H. Morin(3,5,7,2′,4′-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter(hURAT1) expressed in human embryonic kidney cells[J]. Drug Metab Dispos, 2007, 35(6):981-986.
[41]
MO S F, ZHOU F, LV Y Z, et al. Hypouricemic action of selected flavonoids in mice:Structure-activity relationships[J]. Biol Pharm Bull, 2007, 30(8):1551-1556.
[42]
ENOMOTO A, KIMURA H, CHAIROUNGDUA A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature, 2002, 417(6887):447-452.
[43]
ZHANG J, PENG Q, SHI S, et al. Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system(SNEDDS) loaded with morin-phospholipid complex[J]. Int J Nanomed, 2011, 6:3405-3414.
[44]
ZHANG J, SHUAI X, LI J, et al. Biodistribution, hypouricemic efficacy and therapeutic mechanism of morin phospholipid complex loaded self-nanoemulsifying drug delivery systems in an experimental hyperuricemic model in rats[J]. J Pharm Pharmacol, 2016, 68(1):14-25.
[45]
WADDAD A Y, ABBAD S, YU F, et al. Formulation, characterization and pharmacokinetics of morin hydrate niosomes prepared from various non-ionic surfactants[J]. Int J Pharm, 2013, 456(2):446-458.
[46]
LI J, YANG Y, LU L, et al. Preparation, characterization and systemic application of self-assembled hydroxyethyl starch nanoparticles-loaded flavonoid morin for hyperuricemia therapy[J]. Int J Nanomed, 2018, 13:2129-2141.
[47]
MERWID-LAD A, TROCHA M, CHLEBDA E, et al. Effects of morin-5′-sulfonic acid sodium salt(NaMSA) on cyclophosphamide-induced changes in oxido-redox state in rat liver and kidney[J]. Hum Exp Toxicol, 2012, 31(8):812,819.
[48]
MATHUR A, RIZVI F,KAKKAR P. PHLPP2 down regulation influences nuclear Nrf2 stability via Akt-1/Gsk3β/Fyn kinase axis in acetaminophen induced oxidative renal toxicity:Protection accorded by morin[J]. Food Chem Toxicol, 2016, 89:19-31.
[49]
KALTALIOGLU K,COSKUN-CEVHER S. Potential of morin and hesperidin in the prevention of cisplatin-induced nephrotoxicity[J]. Ren Fail, 2016, 38(8):1291-1299.
[50]
MILLER R P, TADAGAVADI R K, RAMESH G, et al. Mechanisms of cisplatin nephrotoxicity[J]. Toxins(Basel), 2010, 2(11):2490-2518.
[51]
KANDEMIR F M, YıLDıRıM S, KUCUKLER S, et al. Protective effects of morin against acrylamide-induced hepatotoxicity and nephrotoxicity:a multi-biomarker approach[J]. Food Chem Toxicol, 2020, 138:111190.Doi:10.1016/j.fct.2020.111190.
[52]
WEI Z, HE X, KOU J, et al. Renoprotective mechanisms of morin in cisplatin-induced kidney injury[J]. Int Immunopharmacol, 2015, 28(1):500-506.
[53]
SINGH M P, CHAUHAN A K,KANG S C. Morin hydrate ameliorates cisplatin-induced ER stress, inflammation and autophagy in HEK-293 cells and mice kidney via PARP-1 regulation[J]. Int Immunopharmacol, 2018, 56:156-167.
[54]
K V A, MADHANA R M, KASALA E R, et al. Morin hydrate mitigates cisplatin-induced renal and hepatic injury by impeding oxidative/nitrosative stress and inflammation in mice[J]. J Biochem Mol Toxicol, 2016, 30(12):571-579.
[55]
BURDA S,OLESZEK W. Antioxidant and antiradical activities of flavonoids[J]. J Agric Food Chem, 2001, 49(6):2774-2779.
[56]
HEIM K E, TAGLIAFERRO A R,BOBILYA D J. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships[J]. J Nutr Biochem, 2002, 13(10):572584.
[57]
WOLFE K L,LIU R H. Structure-activity relationships of flavonoids in the cellular antioxidant activity assay[J]. J Agric Food Chem, 2008, 56(18):8404-8411.
[58]
KIM J M, LEE E K, PARK G, et al. Morin modulates the oxidative stress-induced NF-kappaB pathway through its anti-oxidant activity[J]. Free Radic Res, 2010, 44(4):454-461.
[59]
GU T T, SONG L, CHEN T Y, et al. Fructose downregulates mir-330 to induce renal inflammatory response and insulin signaling impairment:attenuation by morin[J]. Mol Nutr Food Res, 2017, 61(8).Doi:10.1002/mnfr.201600760.
[60]
SINGH M P, SHARMA C,KANG S C. Morin hydrate attenuates adenine-induced renal fibrosis via targeting cathepsin D signaling[J]. Int Immunopharmacol, 2021, 90:107234. Doi:10.1016/j.intimp.2020.107234.
[61]
PABLA N,DONG Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies[J]. Kidney Int, 2008, 73(9):994-1007.
[62]
MO J S, CHOI D, HAN Y R, et al. Morin has protective potential against ER stress induced apoptosis in renal proximal tubular HK-2 cells[J]. Biomed Pharmacother, 2019, 112:108659. Doi:10.1016/j.biopha.2019.108659.
[63]
DANESH F R, SADEGHI M M, AMRO N, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway:Implications for diabetic nephropathy[J]. Proc Natl Acad Sci USA, 2002, 99(12):8301-8305.
[64]
KE Y Q, LIU C, HAO J B, et al. Morin inhibits cell proliferation and fibronectin accumulation in rat glomerular mesangial cells cultured under high glucose condition[J]. Biomed Pharmacother, 2016, 84:622-627.
[65]
KIM J, LONG K E, TANG K, et al.Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity[J]. Kidney Int, 2012, 82(2):193-203.
[66]
CHEN X, GAN Q, FENG C, et al. Investigation of selective binding of inhibitors to PTP1B and TCPTP by accelerated molecular dynamics simulations[J]. J Biomol Struct Dyn, 2019, 37(14):3697-3706.
[67]
GONG E J, PARK H R, KIM M E, et al. Morin attenuates tau hyperphosphorylation by inhibiting GSK3β[J]. Neurobiol Dis, 2011, 44(2):223-230.
[68]
DEOLIVEIRA T T, NAGEM T J, DEMIRANDA L C G, et al. Inhibitory action on aldose reductase by soybean flavonoids[J]. J Braz Chem Soc, 1997, 8(3):211-213.
[69]
TIAN W X. Inhibition of fatty acid synthase by polyphenols[J]. Curr Med Chem, 2006, 13(8):967-977.
[70]
PAOLI P, CIRRI P, CASELLI A, et al. The insulin-mimetic effect of morin: a promising molecule in diabetes treatment[J]. Biochim Biophys Acta, 2013, 1830(4):3102-3111.
[71]
LIANG X, WANG P, CHEN B, et al. Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease[J]. Kidney Int, 2020, 97(1):175-192.
[72]
ELGAMAL H,MUNUSAMY S. Aldose reductase as a drug target for treatment of diabetic nephropathy:Promises and challenges[J]. Protein Pept Lett, 2017, 24(1):71-77.
[73]
THONGNAK L, PONGCHAIDECHA A,LUNGKAPHIN A. Renal lipid metabolism and lipotoxicity in diabetes[J]. Am J Med Sci, 2020, 359(2):84-99.
[74]
RIZVI F, MATHUR A, KRISHNA S, et al. Suppression in PHLPP2 induction by morin promotes Nrf2-regulated cellular defenses against oxidative injury to primary rat hepatocytes[J]. Redox Biol, 2015, 6:587-598.
2023, Vol. 58 
